Taselisib Hits, but Barely Slows, PI3KCA-Mutated Breast Cancer Taselisib Hits, but Barely Slows, PI3KCA-Mutated Breast Cancer

The investigational targeted therapy is somewhat effective, but has the downside of significant additional toxicity.Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news